Companies / Belgium
Industry Consolidation To Bring Long-Term Benefits
October 2006 | Company News AlertContinuing the consolidation trend in the European pharmaceutical sector, Belgian firm UCB has unveiled a EUR4.4bn (US$5.6bn) bid for German company Schwarz Pharma to create major biopharmaceutical player specialising in neurology, inflammation and oncology.
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
